Birchcreek Wealth Management LLC Acquires 195 Shares of Novo Nordisk A/S (NYSE:NVO)

Birchcreek Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,542 shares of the company’s stock after acquiring an additional 195 shares during the period. Birchcreek Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $303,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Sheaff Brock Investment Advisors LLC raised its position in Novo Nordisk A/S by 4.5% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 3,470 shares of the company’s stock valued at $413,000 after purchasing an additional 150 shares in the last quarter. CIBC Asset Management Inc grew its stake in Novo Nordisk A/S by 3.7% during the 3rd quarter. CIBC Asset Management Inc now owns 69,558 shares of the company’s stock worth $8,194,000 after buying an additional 2,494 shares during the last quarter. Intellectus Partners LLC grew its stake in Novo Nordisk A/S by 9.2% during the 3rd quarter. Intellectus Partners LLC now owns 8,884 shares of the company’s stock worth $1,058,000 after buying an additional 749 shares during the last quarter. Wealthstream Advisors Inc. grew its stake in Novo Nordisk A/S by 3.9% during the 3rd quarter. Wealthstream Advisors Inc. now owns 3,185 shares of the company’s stock worth $379,000 after buying an additional 120 shares during the last quarter. Finally, Zions Bancorporation N.A. grew its stake in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 3.4 %

Shares of NVO traded down $3.63 during midday trading on Friday, hitting $101.69. 690,363 shares of the stock were exchanged, compared to its average volume of 4,424,134. The firm has a market cap of $456.34 billion, a P/E ratio of 32.91, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a fifty day simple moving average of $119.17 and a 200 day simple moving average of $129.75.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.